A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancerOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared gut microbiota in 44 colorectal cancer (CRC) patients versus 20 healthy controls, and linked microbial patterns to tumor gene mutations.
How was it studied?
Fecal samples underwent 16S rRNA gene sequencing for all participants. Targeted next-generation sequencing of formalin-fixed paraffin-embedded tumor tissue identified somatic mutations in 39 of the CRC patients.
What did they find?
CRC patients had lower microbial diversity and higher levels of Bifidobacterium, Bacteroides, and Megasphaera, while healthy controls showed more Collinsella, Faecalibacterium, and Agathobacter. APC mutations occurred in 77 percent (30 of 39) of CRC patients, the highest rate observed. KRAS mutant tumors were associated with Faecalibacterium, Roseburia, Megamonas, Lachnoclostridium, and Harryflintia, with KRAS status negatively correlated with Bifidobacterium and positively correlated with Faecalibacterium.
Why it matters
This is among the first studies directly linking specific tumor gene mutations to gut microbiota composition in colorectal cancer. The authors suggest targeted CRC therapy response may relate to gut flora, warranting further investigation.